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Abstract
Introduction T-614 is a novel oral antirheumatic agent for the
treatment of rheumatoid arthritis. Whether it has immunomodulatory
or disease-modifying properties and its mechanism of action are
largely undetermined.
Methods Rats with collagen-induced arthritis (CIA) were treated
with T-614 (5 and 20 mg/kg) daily. Animals receiving methotrexate
(1 mg/kg every 3 days) and the nonsteroidal anti-inflammatory agent
nimesulide (10 mg/kg per day) were used as controls. A
combination therapy group was treated with both T-614(10 mg/kg
per day) and methotrexate (1 mg/kg every 3 days). Hind paw
swelling was evaluated and radiographic scores calculated. Serum
cytokine levels were assessed by Bio-plex analysis. Quantitative
PCR was used to evaluate expression of mRNA for interferon-γ, IL-
4 and IL-17. Serum IL-17 and anti-type II collagen antibodies (total
IgG, IgG1, IgG2a, IgG2b and IgM) were measured using ELISA.
Results Oral T-614 inhibited paw swelling and offered significant
protection against arthritis-induced cartilage and bone erosion,
comparable to the effects of methotrexate. CIA rats treated with T-
614 exhibited decreases in both mRNA expression of IL-17 in
peripheral blood mononuclear cells and lymph node cells, and
circulating IL-17 in a dose-dependent manner. T-614 also reduced
serum levels of tumor necrosis factor-α, IL-1β and IL-6. A
synergistic effect was observed for the combination of methotrexate
and T-614. In addition, T-614 (20 mg/kg per day) depressed
production of anti-type II collagen antibodies and differentially
affected levels of IgG2a subclasses in vivo, whereas IgM level was
decreased without any change in the IgG1 level. Together, the
findings presented here indicate that the novel agent T-614 has
disease-modifying effects against experimental arthritis, as
opposed to nimesulide.
Conclusions Our data suggested that T-614 is an effective
disease-modifying agent that can prevent bone/cartilage
destruction and inflammation in in CIA rats. Combination with
methotrexate markedly enhances the therapeutic effect of T-614.
Introduction
T-614 (N-[7-[(methanesulfonyl)amino]-4-oxo-6-phenoxy-4H-1-
benzopyran-3-yl] formamide) is a novel immunomodulator. Pre-
vious research indicated that it could reduce immunoglobulin
production by acting directly on B lymphocytes in both mice
and humans, despite having no notable action on B-lym-
phocyte proliferation [1]. It also suppressed inflammatory
cytokine production in cultured human synovial cells induced
by tumor necrosis factor (TNF)-α by inhibiting the activity of
nuclear factor-κB [2,3]. Reflecting laboratory findings, we
observed significant improvements in rheumatoid arthritis (RA)
in clinical trials [4]. The molecular mechanisms by which T-614
alters an ongoing immune response in vivo are not yet clear.
Rheumatoid arthritis (RA) is a complicated and treatment-
refractory autoimmune disease that is characterized by a
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chronic inflammatory infiltrate of immune cells, in particular T
cells, which represent approximately 40% of the synovial cel-
lular infiltration and participate in a number of inflammatory and
destructive events, such as synovial hyperplasia, pannus for-
mation, cartilage and bone erosion, and joint malformation [5-
8]. RA was previously considered to be a T-helper (Th)1-driven
disease with a relative predominance of IFN-γ and lack of Th2
cytokines, leading to induction and persistence of disease.
This was challenged by the demonstration that IL-17-produc-
ing T cells ('Th17' cells), and not IFN-γ CD4+ effector T cells,
are pathogenic in collagen-induced arthritis (CIA) [9,10]. Liga-
tion of the IL-17 receptor, which is expressed on several cell
types (including epithelial cells, endothelial cells, and fibrob-
lasts), induces the secretion of IL-6, IL-8, granulocyte colony-
stimulating factor, monocyte chemotactic protein-1, prostag-
landin E2, TNF-α and IL-1β, as well as neutrophil chemotaxis
and granulopoiesis [11-14]. IL-17 also induces the expression
of matrix metalloproteinase-1 and -13 in RA synovial cells and
osteoblasts [15,16], and induces the expression of RANKL
(receptor activator of nuclear factor-κB ligand), which contrib-
utes to bone resorption [16].
Relative to other experimental arthritis models, CIA has been
demonstrated to resemble human RA more closely in terms of
clinical, histological and immunological features, as well as
genetic linkage [17,18]. Dysregulated Th17 cell responses
have been linked to the induction and progression of both CIA
and RA. Local over-expression of IL-17 increases the severity
of murine arthritis [19], and neutralizing anti-IL-17 antibody
reduces the severity of arthritis [20]. IL-17-deficient mice have
reduced incidence and severity of CIA [21]. An inhibitory
effect on Th17 cells has been demonstrated for only a few
drugs to date, including cyclosporine A [22] and entanercept
[23].
In the present work we aimed to confirm the immunoregulatory
effect of T-614, especially on Th17 cells, in CIA in rats. As a
comparator drug, we evaluated the effect of methotrexate
(MTX), one of the classical disease-modifying antirheumatic
drugs (DMARDs) and the one that is most commonly used in
clinical therapy, in CIA rats. We demonstrated that treatment
of rats with T-614 dramatically suppressed disease progres-
sion, and markedly protected affected joints against cartilage
destruction and bone erosion in a dose-dependent manner.
Alleviation of Th17 cell differentiation and serum levels of IL-17
were first confirmed in CIA rats treated with T-614. The proin-
flammatory cytokines IL-6, TNF-α, and IL-β were decreased by
treatment with T-614 (most significantly so for IL-6), contribut-
ing to the therapeutic effect of this agent. Even at low dose, T-
614 in combination with MTX was able to inhibit the develop-
ment of CIA completely. In addition, a comparison of T-614
with MTX suggested that T-614, but not MTX, inhibits the pro-
duction of arthritogenic antibodies. In addition, nimesulide (an
effective cyclo-oxygenase [COX]-2 inhibitor) depressed the
edema and soft tissue swelling markedly in early disease, but
it exhibited little inhibition of cartilage destruction and bone
erosion. These findings indicate that T-614 exerts its immu-
noregulatory effect by skewing responses away from Th17,
and by depression of antibody formation, which illustrate its
unique character as a novel DMARD.
Materials and methods
Materials
T-614 was kindly provided by Simcere Pharmaceutical (Nan-
jing, China). Female Wistar rats (aged 6 to 7 weeks old, body
weight 180 to 190 g) were purchased from the Laboratory
Animal Services Center of the Shanghai Jiaotong University,
School of Medicine (Shanghai, China). Animals were housed
four per cage in rooms maintained at 20 ± 1°C with an alter-
nating 12-hour light-dark cycle. Food and water were provided
ad libitum throughout the experiments. Animals were acclima-
tized to their surroundings over 1 week to eliminate the effect
of stress before initiation of the experiments. All of the experi-
mental protocols involving animals and their care were
approved by the Committee on Use of Human & Animal Sub-
jects in Teaching and Research of the Shanghai Jiaotong Uni-
versity School of Medicine, and were carried out in
accordance with the regulations of the Department of Health
of Shanghai.
Induction of CIA in rats and T-614 treatment
CIA was induced in female Wistar rats using a method
described previously [24]. Briefly, rats were subcutaneously
injected at the base of the tail with 200 μg bovine type II col-
lagen (CII; Chondrex, Redmond, WA, USA) emulsified in com-
plete Freund's adjuvant (Sigma, Redmond, WA, USA). On day
7 after primary immunization, all the rats were given an intra-
dermal booster injection of 100 μg CII in incomplete Freund's
adjuvant on the back (Sigma, Redmond, WA, USA). Onset of
arthritis in ankle joints usually became visually apparent
between days 10 and 12.
In the therapeutic treatment protocol for established CIA, all
rats received treatment or vehicle (orally admininstered) from
the day after onset of arthritis (day 12) until day 36 of the
experiment. The rats received T-614 (daily dose 5 or 20 mg/
kg body weight), nimesulide (Tocris Cookson, Ellisville, MO,
USA; daily dose 10 mg/kg body weight), vehicle (0.5% CMC
solution [vehicle] once daily), or MTX (Sigma, St. Louis, MO,
USA; 1 mg/kg body weight every 3 days). Rats in the combi-
nation therapy group were administrated both MTX (1 mg/kg
every 3 days) and T-614 (5 mg/kg per day).
Evaluation of the development of arthritis
Clinical arthritis was observed daily and severity was assessed
using a semiqualitative clinical score [25] as follows: 0 = nor-
mal, without any macroscopic signs of arthritis; 1 = mild, but
definite redness and swelling of the ankle, or apparent redness
and swelling limited to individual digits, regardless of the
number of affected digits; 2 = moderate redness and swellingAvailable online http://arthritis-research.com/content/10/6/R136
Page 3 of 11
(page number not for citation purposes)
of the ankle; 3 = redness and swelling of the entire paw includ-
ing digits; or 4 = maximally inflamed limb with involvement of
multiple joints. In these studies, the maximum score was 8,
which was the sum of scores from both hind paws of each ani-
mal.
Radiographic assessments
Magnetic resonance imaging (MRI) was performed at day 21
with a 1.5 T magnetic resonance scanner Excite HD (General
Electric Medical Systems, Milwaukee, WI, USA) using a 3-inch
surface coil to obtain coronal short time inversion recovery
(STIR) sequences. The acquisition parameters were as fol-
lows: repetition time 3,900 milliseconds, echo time 42.5 milli-
second, field of view 60 mm, matrix 192 × 160 pixels, slice
thickness 2 mm, interslice gap 0.2 mm, and scan time 2 min-
utes 18 seconds. In addition, coronal T1-weighted sequences
were obtained (repetition time 540 milliseconds, echo time
16.1 milliseconds, field of view 60 mm, matrix 192 × 256 pix-
els, slice thickness 2 mm, interslice gap 0.2 mm, and scan time
2 minutes 18 seconds). MRI bone marrow edema was identi-
fied as hyperintense lesions on STIR sequences, with less
clearly defined margins and intact trabecular structures [26].
High-resolution digital radiographs (24 kV, 40 mAs) of hind
limbs were taken on all animals on day 36. Rats were given a
score from 0 to 3 for each hind limb, with a summated maxi-
mum score of six based on the extent of soft tissue swelling,
joint space narrowing, bone destruction, and periosteal new
bone formation (0 = normal; 1 = soft tissue swelling only; 2 =
soft tissue swelling and early erosions; and 3 = severe ero-
sions).
Micro-computed tomography (CT) scans were done at the
Shanghai Institute of Traumatology and Orthopaedics. Ankle
bones were exposed to nondestructive three-dimensional
imaging using a GE Medical Systems (London, Ontario) RS-9
In Vivo Micro-CT Scanner. The specimens were scanned on
the micro-CT unit using the medium resolution (43.5 μm voxel
dimensions in x, y, and z) scan mode. All scans were calibrated
using samples of water, air, and a bone standard in order to
allow consistent gray-level settings to be used when viewing
the micro-CT images. A central sagittal section was generated
for analysis from each mouse ankle bone image set using soft-
ware available on the scanner console. Measurements of
defection of the ankle bone were made using the software pro-
vided by the scanner manufacturer (MicroView, Waukesha,
Wisconsin, USA).
RNA extraction and real-time PCR analysis of IFN-γ, IL-4 
and IL-17 expression
Total RNA was isolated from lymphocyte cells extracted with
the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and
reverse-transcribed using Sensiscript RT Kit (Fermentas, Bur-
lington, Canada). mRNA expression for rat β-actin, IFN-γ, IL-4
and IL-17 was determined by real-time PCR using SYBR
Green Master Mix (Applied Biosystems, Foster City, Califor-
nia, USA). The primers used are summarized in Table 1.
Thermocycler conditions included an initial holding at 50°C for
2 minutes, then 95°C for 10 minutes. This was followed by a
two-step PCR program: 95°C for 15 seconds and 60°C for 60
seconds for 40 cycles. Data were collected and quantitatively
analyzed on an ABI PRISM 7900 sequence detection system
(Applied Biosystems). The β-actin gene was used as an
endogenous control. The amount of gene expression was then
calculated as the difference cycle threshold (ΔCT) between
the CT value of the target gene and β-actin. ΔΔCT is the differ-
ence between the ΔCT values of the test sample and the con-
trol. Relative expression of target genes was calculated as 2-
ΔΔCT.
Measurements of serum IL-17, TNF-α, IL-1β and IL-6 
levels
Levels of the proinflammatory cytokines TNF-α, IL-1β and IL-6
in blood serum were measured up to day 28 for therapeutic
treatments using commercially available Bio-plex kits
(Research & Development, California, USA), in accordance
with the manufacturers' recommendations. Serum specimens
for IL-17 detection were analyzed by ELISA. Microtiter plates
were coated with antibody of IL-17 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) overnight at 4°C, and then blocked
(0.01 mol/l phosphate-buffered saline [PBS]/0.05% bovine
serum albumin; this solution was used for all further dilutions)
for 2 hours at 37°C. Rat sera were diluted with PBS at 1:20
and added in duplicate wells. Plates were incubated for 2
hours, and subsequently horseradish peroxidase-conjugated
Table 1
Primers used
Molecule Sense Antisense
β-actin 5'-AGGCCAACCGTGAAAAGATG-3' 5'-ACCAGAGGCATAC AGGGACAA-3'
IFN-γ 5'-GAAAGACAACCAGGCCATCAG-3' 5'-TCATGAATGCATCCTTTTTTGC-3'
IL-4 5'-CCACGGAGAACGAG CTCATC-3' 5'-GAGAACCCCAGACTTGTTCTTCA-3'
IL-17 5'-GGGAAGTTGGACCACCACAT-3' 5'-TTCTCCACCCGGAAA GTGAA-3'Arthritis Research & Therapy    Vol 10 No 6    Du et al.
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goat anti-rat antibody were added and incubated for 45 min-
utes. At every step, plates were washed three times with 0.01
mol/l PBS containing 0.05% Tween-20. 3,3',5,5'-Tetramethyl-
benzidine were used for color development. Absorbance (mU)
was read at 450 nm and values were expressed as mean ±
standard error of the mean (Bio-Rad Laboratories, Hercules,
CA, USA).
Measurement of type II collagen antibodies
Antibody titers to type II collagen were assayed by ELISA.
Nunc Maxisorb plates were coated with 100 μl of bovine nasal
collagen II (5 μg/ml in PBS) overnight at 4°C, and then
blocked (0.01 mol/l PBS/0.05% bovine serum albumin; this
solution was used for all further dilutions) for 2 hours at 37°C.
Serum samples were diluted 1:1,000, and 100 μl was added
to the coated 96-well plate and incubated at 37°C for 2 hours,
followed by a 2-hour incubation with a horseradish peroxidase-
linked goat anti-rat IgG antibody (KPL, Gaithersburg, MD,
USA) and mouse anti-rat IgG1, IgG2a, IgG2b and IgM antibody
(Southern Biotech, Birmingham, AL, USA). At every step,
plates were washed three times with 0.01 mol/l PBS contain-
ing 0.05% Tween 20. Absorbance (mU) was read at 450 nm
and values were expressed as mean ± standard error of the
mean. Optical density was measured using Microplate compu-
ter software (Bio-Rad Laboratories).
Data analysis
Significant changes in clinical arthritis as a result of drug treat-
ment were determined using a dynamic modeling approach,
assuming a linear fit for the slope of arthritis progression for
each individual animal (SAS Institute, Inc., Cary, NC, USA).
Significant differences in serum cytokines and antibody levels
were assessed using the Student's t-test, and P < 0.05 was
considered statistically significant. The clinical and radiologi-
cal score was analyzed using nonparametric analysis; Mann-
Whitney test was used when two groups were compared. To
test for differences in trends during the study among study
groups, we used Kruskal-Wallis method followed by Dunn's
test to evaluate differences in each of the study groups from
days 12 to day 30, adjusted to baseline values at day 12.
Results
Decrease in the development of collagen induced 
arthritis rats treated with T-614
The CIA model is characterized by aggressive synovitis, exten-
sive pannus formation, cartilage degradation, and focal bone
erosion. We investigated whether the protective activity of T-
614 was mediated through a decrease in the severity of all of
these clinical indices, or whether the activity of T-614 affected
only specific pathogenetic processes. As shown in Figure 1,
even after the onset of arthritis, T-614 (5 and 20 mg/kg per
day) markedly reduced arthritic scores in the arthritic rats in a
dose-dependent manner, as compared with the vehicle-
treated arthritic rats.
Progression of disease was indicated by increased edema
and erythema of one or both ankle joints, followed by involve-
ment of the metatarsal and interphalangeal joints. Fully devel-
oped arthritis, including red and swollen paws, was observed
8 to 10 days after onset of inflammation. The clinical score in
the vehicle-treated group reached a peak approximately 20
days after the first immunization (maximum arthritis score of
5.75 ± 0.5; P < 0.01, versus day 12). Treatment with MTX (1
mg/kg every 3 days) was efficacious and resulted in a delayed
peak (day 24) and also reduced clinical arthritis significantly at
day 20 (clinical score 3.5 ± 0.57; P < 0.0286, versus vehicle).
Signs of moderate arthritis were observed in rats treated with
a low dose of T-614 (5 mg/kg), which became most severe at
day 18 (maximal clinical score = 2.5 ± 0.6; P = 0.0286, versus
day 12) and improved significantly at day 20 (clinical score =
2.5 ± 1; P = 0.0286, versus vehicle). The high-dose T-614 (20
mg/kg per day) and combination treatments almost completely
Figure 1
Effects of therapeutic treatment with T-614 on disease progression in rats with established CIA Effects of therapeutic treatment with T-614 on disease progression in rats with established CIA. Rats were orally treated daily with T-614 at 5 mg/kg 
per day or 20 mg/kg per day; MTX at 1 mg/kg every 3 days; nimesulide at 10 mg/kg per day; T-614 at 10 mg/kg per day and MTX at 1 mg/kg every 
3 days; or vehicle. Treatment began on day 12 after immunization with type II collagen until day 36. Data are expressed as mean ± standard error of 
the mean (n = 5 to 7). *P < 0.05, **P < 0.01, versus day 12 or the vehicle-treated rats. CIA, collagen-induced arthritis; MTX, methotrexate.Available online http://arthritis-research.com/content/10/6/R136
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suppressed progression; maximal clinical scores in these rats
were 1.75 ± 0.9 at day 24 and 1.73 ± 0.8 at day 22, respec-
tively (P > 0.05, versus day 12). The clinical score in the high-
dose T-614 and combined treatment groups was found to be
statistically significantly lower than that in the control group at
day 20; the maximal clinical scores in these two groups were
1.75 ± 0.975 and 1.75 ± 0.79, respectively (P < 0.05, versus
vehicle). Measurements of paw thickness and paw circumfer-
ence were consistent with clinical scores (data not shown).
Decrease in the severity of inflammation in collagen 
induced arthritis rats treated with T-614
The morphologic changes in the joint architecture of CIA rats
were further assessed using MRI, 21 days after the first immu-
nization. MRI soft tissue swelling is defined based on penetra-
tion of subcutaneous soft tissues and bone marrow on the T1-
weighted image within normal hyperintense subcutaneous
soft tissues and bone marrow. This corresponds to findings on
the STIR image (Figure 2a), in which the damage can be seen
as a clearly demarcated zone of hyperintense signal within nor-
mal hypointense area at this site (arrowhead).
Joints of naïve (non-CIA) rats exhibited intact joint architecture.
The talus, phalanges, talocalcaneal joints, talonavicular articu-
lations and cuneonavicular joints were well defined. Joints
from the vehicle-treated CIA group exhibited significant dam-
age as well as swelling of soft tissues and marked bone mar-
row edema. T-614 had a dose-related efficacy. Joints from rats
Figure 2
Effects of therapeutic treatment with T-614 on inflammation in the CIA rats Effects of therapeutic treatment with T-614 on inflammation in the CIA rats. (a) STIR magnetic resonance images of hind paws from CIA rats. The 
presence of soft tissue swelling (yellow arrow) and localization of bone marrow edema (yellow triangle) are highlighted. Neither paw swelling nor 
bone marrow edema was seen in normal rats (subpanel a). Severe soft tissue swelling and bone erosion were seen in CIA rats treated with vehicle 
(subpanel b). Similar damage was observed in rats treated with nimesulide (subpanel d), but much less damage was seen in rats treated with MTX 
(subpanel c), T-614 (subpanels e and f), and combination treatment with T-614 and MTX (subpanel g). (b) Magnetic resonance imaging score of 
soft tissue swelling in treated CIA rats. Data are expressed as mean ± standard error of the mean (n = 3 to 5). *P < 0.05, **P < 0.01, versus vehicle-
treated arthritic rats. CIA, collagen-induced arthritis; MTX, methotrexate.Arthritis Research & Therapy    Vol 10 No 6    Du et al.
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treated with MTX (1 mg/kg every 3 days) or nimesulide (10
mg/kg per day) also exhibited moderate damage, whereas
nimesulide was associated with much less inhibition of bone
marrow edema. Joints from the T-614 (20 mg/kg per day)
alone and combination therapy group exhibited significant inhi-
bition of damage, which closely resembled the joints from the
naïve rats. As shown in Figure 2b, the mean MRI soft tissue
swelling scores in vehicle-treated (5 ± 0.45) and nimesulide-
treated rats (3.8 ± 0.37; P = 0.96, versus vehicle) were signif-
icantly higher than those in rats treated with low-dose T-614
(3.6 ± 0.4; P = 0.0479, versus vehicle), high-dose T-614 (2.8
± 0.37; P = 0.0159 versus vehicle), and MTX (3.4 ± 0.25; P
= 0.0318, versus vehicle). The hind paws of CIA rats receiving
combined treatment with MTX and T-614 exhibited complete
protection, with the lowest soft tissue swelling scores (1.8 ±
0.38; P = 0.0079, versus vehicle).
Preservation of the structural integrity of affected joints 
by T-614 treatment
The hind paws were further examined by radiography and
micro-CT at day 36. Radiographic severity of joint destruction
in the ankle joints of rats treated with T-614 was markedly
reduced compared with those in the MTX-treated and
nimesulide-treated CIA rats. Representative radiographs of
the hind paws from vehicle, MTX, nimesulide and T-614 rats
are shown in Figure 3a. Radiological analysis revealed severe
bone erosion in the joints of CIA rats, as shown in Figure 3b.
The mean bone erosion scores in vehicle (4.4 ± 0.25) and
nimesulide rats (4.8 ± 0.38; P = 0.309, versus vehicle) were
significantly higher than those in rats receiving low-dose T-614
(3.2 ± 0.58; P = 0.015, versus vehicle), high-dose T-614 (2.6
± 0.5; P = 0.007, versus vehicle), and MTX (2.8 ± 0.37; P =
0.009, versus vehicle). The hind paws of CIA rats receiving
combined treatment with MTX and T-614 exhibited complete
protection, with the lowest scores for bone erosion (1.6 ±
0.24; P = 0.007, versus vehicle). The data also indicate that
MTX markedly inhibited the bone erosion of the arthritic joints,
as did T-614 (5 mg/kg per day), but not the soft tissue swell-
ing.
We further investigated the effect of T-614 treatment on struc-
tural preservation of hind joints in rats with established disease
by three-dimensional micro-CT imaging, which permits nonin-
vasive visualization of pathologic joint changes (Figure 3c).
Images of a naïve rat joint revealed intact joint architecture as
well as normal bone surfaces. The various bones that consti-
tute the joint, namely the distal tibia/fibula, talus and cal-
caneus, were clearly resolved. The joint from the CIA rats
treated with vehicle and nimesulide exhibited marked erosion
of several bone surfaces, especially at the junction of the distal
tibia and fibula and along the length of the calcaneus. Degen-
erative changes were also visible on the talus. Compared with
CIA rats treated with MTX and low-dose T-614, those CIA rats
treated with either high dose (20 mg/kg per day) T-614 alone
or 10 mg/kg per day T-614 combined with MTX resulted in
much more significant protection against bone destruction,
preservation of the architecture of the affected hind joints, and
protection against degenerative changes. Isolated regions of
bone erosion could be visualized, but the integrity of the joint
architecture was clearly preserved.
Skewing of responses away from Th17 in CIA by T-614 
treatment
Expression levels of transcripts for T-cell differentiation related
genes, namely IFN-γ, IL-4 and IL-17, in the inguinal lymph node
and peripheral blood mononuclear cells (PBMCs) were ana-
lyzed on day 21 after immunization with CIA (Figure 4a). levels
of IL-4 and IL-17 decreased sharply in the PBMCs from high-
dose T-614 and combination treated rats. In particular, T-614
inhibited the elevated IL-17 expression in inguinal lymph node
cells in a dose-dependent manner. IFN-γ and IL-17 mRNA lev-
els, but not those of IL-4, decreased significantly in lymph
nodes of rats treated with MTX. No treatment was able to
depress the elevated IFN-γ expression in PBMCs.
Levels of proinflammatory cytokines TNF-α, IL-1β, and IL-6 in
blood serum were analyzed using a multiplex immunoassay on
day 28 after immunization with CIA. IL-17 level was determi-
nated by ELISA analysis. Consistent with the joint swelling,
TNF-α, IL-1β, IL-6, and IL-17 in the vehicle-treated CIA rats
were systemically over-produced in serum. The elevated IL-6
and IL-17 levels in rats treated with T-614 were decreased in
a dose-dependent manner and correlated positively with the
degree of joint swelling in individual animals. T-614 at the dose
of 20 mg/kg only, but not at 5 mg/kg, significantly reduced
serum levels of TNF-α and IL-1β (Figure 4b).
Disease attenuation is also partly attributable to 
inhibition of humoral collagen-specific immunity
T-614, but not MTX, strongly inhibited the increase in CII anti-
body. To determine the effect of T-614 on immunoglobulin
subclasses, the total serum levels of IgM, IgG1, IgG2a, and
IgG2b subclasses were quantified. As shown in Figure 5, there
was no significant difference in total IgG-CII antibody (P <
0.05) between MTX, nimesulide and low-dose T-614 groups
compared with the vehicle control. Anti-CII antibody levels in
sera from rats treated with combination therapy were markly
decreased, as were levels of IgG1, IgG2a, IgG2b and IgM. High-
dose T-614 (20 mg/kg per day) also decreased levels of total
IgG, IgG2a and IgM, whereas low-dose T-614 (5 mg/kg per
day) affected only the level of IgG2a. Moreover, the IgG2a level
was also decreased in the MTX group.
Discussion
RA is a complicated and treatment-refractory autoimmune dis-
ease, with complex pathogenesis and involving pathological
changes in multiple targets [5,27,28]. The joint targeted effec-
tor mechanism of the classical model is probably quite com-
plex, involving T-cell stimulation of synovial cells, T-cell
independent mesenchymal activation, and an arthritogenicAvailable online http://arthritis-research.com/content/10/6/R136
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effect in which antibodies bind to cartilage. The proinflamma-
tory cytokines, mainly TNF-α, IL-1β and IL-6, are considered
powerful targets in the treatment of RA [29-31]. The new bio-
logic agents, despite their substantial efficacy and ability to
bring about clinical improvement, are expensive and cause
hypersensitivity to medications and infections [32-34].
Because long-term experience with anti-TNF therapy is limited,
the potential long-term risks, particularly of developing lympho-
mas, remains an issue [30]. Until these concerns are fully
addressed, nonbiologic DMARDs will probably remain the pre-
ferred initial treatments for RA [35,36]. Because of its multi-
suppressive properties, T-614 is expected to be applied in
treatment of RA independently or combined with other
DMARDs such as MTX, an analog of folic acid and of aminop-
terin. MTX was therefore included as a standard control in our
studies because of its dramatic effects on arthritis in rat mod-
els [37]. Nimesulide, an effective COX-2 inhibitor, was also
tested to identify the role played by nonsteroidal anti-inflamma-
tory drugs in the development of CIA.
Clearly, both T-614 and MTX efficiently suppress the CIA
model after the onset of arthritis. Soft tissue swelling and bone
Figure 3
Effects of treatment with T-614 on structural integrity in CIA rats Effects of treatment with T-614 on structural integrity in CIA rats. (a) Macroradiographs of rat hind paws. Neither paw swelling nor joint damage was 
observed in normal rats (subpanel a). Severe bone matrix resorption and erosion were seen in CIA rats treated with vehicle (subpanel b). Similar 
damage was observed in rats treated with nimesulide (subpanel d), but the damage was much less in rats treated with MTX (subpanel c), T-614 
(subpanels e and f), and both of them (subpanel g). (b) Radiologic score of bone erosion in treated CIA rats. Data are expressed as mean ± stand-
ard error of the mean (n = 3 to 5). *P < 0.05, **P < 0.01 versus the vehicle-treated rats. (c) All images were obtained using a RS-9 in Vivo Micro-CT. 
Neither joint damage nor bone loss was seen in normal rats (subpanel a). Severe bone matrix resorption, erosion joint, and bone loss were seen in 
CIA rats treated with vehicle (subpanel b). Similar bone loss was seen in rats treated with nimesulide (subpanel d) but this was much less in rats 
treated with MTX (subpanel c), T-614 (subpanels e and f), and the combination of T-614 and MTX (subpanel g). CIA, collagen-induced arthritis; 
MTX, methotrexate.Arthritis Research & Therapy    Vol 10 No 6    Du et al.
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marrow edema in early CIA were measured, and paw architec-
ture was examined using MRI [38]. Compared with the clinical
score data, MRI results provided more objective and detailed
information. Our findings indicate that low-dose T-614 (5 mg/
kg per day) suppressed autoimmune responses to a degree
similar to that with MTX (1 mg/kg every 3 days), whereas high-
dose T-614 (20 mg/kg per day) almost completely inhibited
the inflammation and bone marrow edema of CIA. When com-
bined with MTX, T-614 (10 mg/kg per day) was able to effect
complete control of the disease process. Inhibition the activity
of COX-2 by nimesulide also depressed the edema of CIA
paws effectively, whereas the bone marrow edema continued
to progress.
The role played by T cells in RA has been highlighted by IL-17,
a T-cell derived proinflammatory cytokine that has been impli-
cated in joint inflammation and destruction [8,39-41].
Because the treatment was started after the onset of arthritis,
it did not affect immune priming following immunization or the
earliest inflammatory events with synovial hyperplasia, infiltra-
tion of inflammatory cells and differentiation of collagen II-spe-
cific T cells. Our data demonstrate the powerful inhibitory and
dose-dependent effect of T-614 on IL-17 levels in local lymph
nodes. The immunomodulatory effect of T-614 is not clear but
it may partly depend on its inhibition of nuclear factor-κB or
other cell signaling pathways [42]. Real-time PCR is sensitive
and allows immediate assessment of mRNA expression, but it
still differs from the protein level. There remains much work to
be done to identify the specific cytokine-secreting T cells and
confirm their differentiation. Bone preservation appeared to be
one of the main benefits of IL-17 inhibition, and this feature
was reflected in the ankle bone volumes calculated quantita-
tively by micro-CT imaging. Rats receiving T-614 at 5 mg/kg
per day exhibited significantly less bone destruction (P  <
0.05), as measured by total bone volume, compared with vehi-
Figure 4
Effects of T-614 on cytokine levels in CIA rats Effects of T-614 on cytokine levels in CIA rats. Rats were orally treated with different doses of T-614, nimesulide, MTX and vehicle, beginning on day 
12 after the immunization with CIA until day 36. (a) Effects of T-614 on mRNA levels of IFN-γ, IL-4 and IL-17 in lymph node and PBMCs from CIA 
rats. (b) Effects of T-614 on serum levels of TNF-α, IL-1β, IL-6 and IL-17 in the CIA rats. CIA, collagen-induced arthritis; IFN, interferon; IL, inter-
leukin; LN, lymph node; MTX, methotrexate; PBMC, peripheral blood mononuclear cell.Available online http://arthritis-research.com/content/10/6/R136
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cle-treated arthritic controls. The bone volumes of rats receiv-
ing T-614 at 20 mg/kg per day and T-614 combined with MTX
remained almost intact. The findings support the view that T-
614 can protect the joints from damage in an inflammatory
environment, in concert with MTX.
Proinflammatory cytokines TNF-α, IL-1β, and IL-6 help to prop-
agate the extension of a local or systemic inflammatory proc-
ess. Similar to the IL-17 levels in serum, markedly low serum
levels of IL-6 were also observed in CIA rats treated with T-
614, even at the dose of 5 mg/kg per day. Only MTX, high-
dose T-614 (20 mg/kg per day) and not low-dose T-614 (5
mg/kg per day), and combination treatment significantly
reduced serum levels of TNF-α and IL-1β. Recent studies have
shown that IL-6, in combination with transforming growth fac-
tor-β, inhibits the generation of FoxP3-expressing T-regulatory
cells and induces the generation of Th17 cells [43]. Th1, Th2,
and Th17 cells develop from naïve T cells; in contrast, the gen-
eration of T-regulatory cells and Th17 cells occurs via alterna-
tive pathways, and they are selected according to the
presence or absence of IL-6, a pleiotropic cytokine that plays
important roles in the regulation of the immune response,
inflammation, and hematopoiesis. Decreased IL-6 production
could contribute to the attenuation of Th17 responses, which
may also explain the therapeutic effect of T-614. IL-6 also
induces activated B cells to differentiate into antibody-produc-
ing cells [44] and promotes the production of vascular
endothelial growth factor, which plays an important role in ang-
iogenesis [45]. Furthermore, in terms of bone metabolism, IL-
6 induces osteoclast differentiation in the presence of soluble
IL-6 receptor, thereby contributing to joint destruction and
osteoporosis [46]. IL-17 significantly induces the synthesis of
IL-6 by synoviocytes and macrophages. A positive feedback
loop initiates and accelerates the progression of CIA. Modula-
tion of inflammatory cytokines and IL-17 by T-614 suggests its
potential therapeutic value in the treatment of other inflamma-
tory diseases, such as ankylosing spondylitis and psoriatic
arthritis.
During the development of CIA, increasing levels of anti-CII
antibodies bind to the collagen of the articular cartilage, acti-
vate the complement system and initiate tissue damage; this
indicates that there is T-B cell cooperation and activation in
vivo [47,48]. More interestingly, T-614 not only suppressed
CII antibody levels but also differentially modulated immu-
noglobulin subclass levels; these effects suggest that it may
be useful for the treatment of lupus or other autoimmune dis-
orders. Similar effects were seen in the combination therapy
group, indicating that there is synergy between T-614 and
MTX. Low-dose T-614 and MTX also had an effect on the level
of IgG2a antibody, indicating that they may operate through T-
cell associated antibodies in the CIA model. Because IgG2a is
the most potent activator of the classical complement cascade
and Fc receptor bearing macrophages, the present findings
add further support to the inhibitory mechanism of T-614 and
the pathogenic role of IgG2a in rat CIA [49].
To summarize, T-614 – a novel immunomodulatory drug –
appears to protect the joints from inflammation injury and oste-
oclastic bone resorption through skewing the response from
primarily a Th17-driven one, and it does so to a greater degree
in combination with MTX. These findings suggest that T-614
is a new candidate for use in combination therapy, which is
Figure 5
Effects of T-614 on serum IgG levels in CIA rats Effects of T-614 on serum IgG levels in CIA rats. Serum was collected on day 36. Anti-CII (total IgG, IgM, IgG1, IgG2a, and IgG2b) levels increased 
as disease progressed. Combination therapy reduced the total anti-CII antibody level significantly, as well as levels of IgM, IgG1, IgG2a, and IgG2b. 
High dose T-614(20 mg/kg per day) also decreased levels of total IgG, IgM and IgG2a, whereas low-dose of T-614 (5 mg/kg per day) or MTX (1 mg/
kg every 3 days) had an effect only on IgG2a level. Data are expressed as mean ± standard error of the mean (n = 5 to 7). *P < 0.05, versus the vehi-
cle-treated rats.Arthritis Research & Therapy    Vol 10 No 6    Du et al.
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increasingly being applied to the treatment of RA and other
Th17-associated inflammatory autoimmune diseases.
Conclusion
In the present experiments, T-614 significantly prevented
bone/cartilage destruction and inflammation in CIA. Further-
more, combination with MTX enhanced the therapeutic effect
of T-614.
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